KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Non-Current Assets (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Non-Current Assets readings, the most recent being $109.8 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 60.42% to $109.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $329.3 million, a 25.54% increase, with the full-year FY2025 number at $109.8 million, up 60.42% from a year prior.
  • Non-Current Assets hit $109.8 million in Q4 2025 for Biocryst Pharmaceuticals, up from $90.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $109.8 million in Q4 2025 to a low of $10.7 million in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $21.5 million (2021), compared with a mean of $42.1 million.
  • Biggest five-year swings in Non-Current Assets: crashed 58.75% in 2023 and later soared 478.69% in 2024.
  • Biocryst Pharmaceuticals' Non-Current Assets stood at $22.0 million in 2021, then surged by 52.17% to $33.5 million in 2022, then tumbled by 37.33% to $21.0 million in 2023, then soared by 226.06% to $68.5 million in 2024, then surged by 60.42% to $109.8 million in 2025.
  • The last three reported values for Non-Current Assets were $109.8 million (Q4 2025), $90.7 million (Q3 2025), and $58.7 million (Q2 2025) per Business Quant data.